Looks like you’re on the UK site. Choose another location to see content specific to your location
ResMed study shows how digital tools aid sleep apnoea treatment adherence
ResMed has announced data from a major new study assessing the benefits of digital connected care models for sleep apnoea patients.
The observational study was the largest of its kind in the world and included more than 128,000 people with sleep apnoea whose devices allow for therapy to be remotely monitored using ResMed's myAir cognitive behaviour-based patient engagement app.
Results from the trial indicated that people who use a self-management app when treating their sleep apnoea with positive airway pressure (PAP) are significantly more likely to stick with their therapy.
More than 87 percent of PAP users were compliant on therapy when supported by myAir and AirView monitoring, compared to 70 percent compliance for those monitored by AirView alone.
ResMed's medical director Adam Benjafield said: "While our study focused on PAP users, we believe these results may be generalised more broadly in terms of the role online tools can have in improving medical treatment compliance overall."
The company also announced its financial results for the first quarter of its 2017 fiscal year this week, during which it achieved a 13 percent year-on-year increase in revenues.
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard